OS7.3 Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients

摘要

REGOMA trial showed that regorafenib (REG) significantly improved OS and PFS in patients (pts) with relapsed GBM with respect to lomustine (LOM). REG showed a different toxicity profile compared to LOM. Here, we report final results of the HRQoL assessment, a secondary end point.